Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: HeatherN who wrote (33711)	4/28/1999 2:40:00 PM
From: MrThesp	Read Replies (1) \| Respond to of 90042

Good point...been a lot of talk about Vioxx/Celebrex lately... When is it set to hit the market? Paul {:-)

To: HeatherN who wrote (33711)	4/28/1999 2:43:00 PM
From: MARK C.	Read Replies (1) \| Respond to of 90042

Heather I agree with you about celebrex and vioxx comparison. I was referring to the time frame of now till the split. Celebrex was first to market and those #'s will be great. Once Vioxx comes out it will likely catch up and exceed celebrex from what I am hearing. I should have been more specific. Yet the #'s will help boost PFE share price over the next 2 months. I also forgot to mention PFE has the best sales force in the industry. Thanks for making the point Heather. :-) MarkC

To: HeatherN who wrote (33711)	4/28/1999 3:22:00 PM
From: Dave	Read Replies (1) \| Respond to of 90042

Heather, Despite the labelling on Celebrex and the data on Vioxx, I doubt you'll see a big clinical difference in either drug. First to market is usually the key with a new class of drugs and Celebrex got there first. That's not to say Vioxx won't do well, because it will, but it's not going to replace Celebrex in any way, shape, or form. I would expect they will both take business from currently used drugs. Dave